39 Kastelein PPTs View free & download

John J'P' Kastelein, MD PhD PowerPoint PPT Presentation

John J'P' Kastelein, MD PhD - ... Chair of the Genetics of Cardiovascular Disease at the Academic Medical Centre ... Academic Medical Center / University of Amsteram. Amsterdam, The Netherlands ...

... Chair of the Genetics of Cardiovascular Disease at the Academic Medical Centre ... Academic Medical Center / University of Amsteram. Amsterdam, The Netherlands ...

| PowerPoint PPT presentation | free to view

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia PowerPoint PPT Presentation

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia - The ENHANCE trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands

The ENHANCE trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands

| PowerPoint PPT presentation | free to download

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia - The ENHANCE trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands

The ENHANCE trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands

| PowerPoint PPT presentation | free to download

Forum On Financing Biotechs: Partnering PowerPoint PPT Presentation

Forum On Financing Biotechs: Partnering - Founded 1996 by Drs. Michael Hayden, Simon Pimstone & John Kastelein (all clinical scientists) ... Spin out. Co-promotion. permutations & combinations of the above) ...

Founded 1996 by Drs. Michael Hayden, Simon Pimstone & John Kastelein (all clinical scientists) ... Spin out. Co-promotion. permutations & combinations of the above) ...

| PowerPoint PPT presentation | free to download

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia - Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia. The ENHANCE trial. ClinicalTrials.gov number: NCT00552097. John J.P. Kastelein, MD, PhD ...

Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia. The ENHANCE trial. ClinicalTrials.gov number: NCT00552097. John J.P. Kastelein, MD, PhD ...

| PowerPoint PPT presentation | free to view

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results PowerPoint PPT Presentation

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results - Title: Impact of Medical Therapies on Coronary Atherosclerosis: Insights from Intravascular Ultrasound Author: Stephen Nicholls Last modified by

Title: Impact of Medical Therapies on Coronary Atherosclerosis: Insights from Intravascular Ultrasound Author: Stephen Nicholls Last modified by

| PowerPoint PPT presentation | free to download

Terapia Combinada: Estatinas Ezetimiba PowerPoint PPT Presentation

Terapia Combinada: Estatinas Ezetimiba - Title: Diapositiva 1 Author: Gabriela Created Date: 1/30/2005 12:53:37 AM Document presentation format: Presentaci n en pantalla Other titles: Arial Wingdings ...

Title: Diapositiva 1 Author: Gabriela Created Date: 1/30/2005 12:53:37 AM Document presentation format: Presentaci n en pantalla Other titles: Arial Wingdings ...

| PowerPoint PPT presentation | free to view

Session 1 Background and Legislative Requirements PowerPoint PPT Presentation

Session 1 Background and Legislative Requirements - ClinicalTrials.gov. Prospective registry. Interventional and observational 'trials' ... QA Process at ClinicalTrials.gov. System of automated and manual checks ...

ClinicalTrials.gov. Prospective registry. Interventional and observational 'trials' ... QA Process at ClinicalTrials.gov. System of automated and manual checks ...

| PowerPoint PPT presentation | free to view

Barrett - Title: No Slide Title Author: Stuart Spechler Last modified by: Stuart Spechler Created Date: 1/28/2003 5:19:01 PM Document presentation format: 35mm Slides

Title: No Slide Title Author: Stuart Spechler Last modified by: Stuart Spechler Created Date: 1/28/2003 5:19:01 PM Document presentation format: 35mm Slides

| PowerPoint PPT presentation | free to view

Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins - The lipid effects of evacetrapib in combination with statins and in dyslipidemia remain unknown. ... rosuvastatin 10 mg) Co-primary endpoints: ...

The lipid effects of evacetrapib in combination with statins and in dyslipidemia remain unknown. ... rosuvastatin 10 mg) Co-primary endpoints: ...

| PowerPoint PPT presentation | free to download

Presentaci - Estudio SHARP Implicaciones en la Prevenci n 2 de la Cardiopat a Isqu mica 1 1 Jos R. Gonz lez Juanatey rea Cardiovascular. Hospital Cl nico Universitario ...

Estudio SHARP Implicaciones en la Prevenci n 2 de la Cardiopat a Isqu mica 1 1 Jos R. Gonz lez Juanatey rea Cardiovascular. Hospital Cl nico Universitario ...

| PowerPoint PPT presentation | free to download

A%20Randomized%20Trial%20of%20Rosuvastatin%20in%20the%20Prevention PowerPoint PPT Presentation

A%20Randomized%20Trial%20of%20Rosuvastatin%20in%20the%20Prevention - PowerPoint Presentation

PowerPoint Presentation

| PowerPoint PPT presentation | free to download

A%20Randomized%20Trial%20of%20Rosuvastatin%20in%20the%20Prevention - PowerPoint Presentation

PowerPoint Presentation

| PowerPoint PPT presentation | free to download

JUPITER Primary Trial End Point: PowerPoint PPT Presentation

JUPITER Primary Trial End Point: - JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death Placebo 251/8901 0.08 HR 0.56, 95% CI 0.46-0.69 P

JUPITER Primary Trial End Point: MI, Stroke, UA/Revascularization, CV Death Placebo 251/8901 0.08 HR 0.56, 95% CI 0.46-0.69 P

| PowerPoint PPT presentation | free to download

Jennifer G. Robinson, MD, MPH, Program Chair PowerPoint PPT Presentation

Jennifer G. Robinson, MD, MPH, Program Chair - An Examination of the ENHANCE Trial Jennifer G. Robinson, MD, MPH, Program Chair President, Midwest Lipid Association Associate Professor Departments of ...

An Examination of the ENHANCE Trial Jennifer G. Robinson, MD, MPH, Program Chair President, Midwest Lipid Association Associate Professor Departments of ...

| PowerPoint PPT presentation | free to download

Can Timing of Exposure Predispose Older Adults to Disease? PowerPoint PPT Presentation

Can Timing of Exposure Predispose Older Adults to Disease? - Leap, Scientific American; 1973. Brain Weight (92%) Nerve Conduction Velocity (90 ... Increased risk of VA with 2-day mean PM2.5, Black Carbon, CO and NO2 for ...

Leap, Scientific American; 1973. Brain Weight (92%) Nerve Conduction Velocity (90 ... Increased risk of VA with 2-day mean PM2.5, Black Carbon, CO and NO2 for ...

| PowerPoint PPT presentation | free to view

of atherosclerosis in patients with abdominal obesity an PowerPoint PPT Presentation

of atherosclerosis in patients with abdominal obesity an - of atherosclerosis in patients with abdominal obesity and coronary artery disease ... Abdominal obesity is associated with specific metabolic abnormalities that ...

of atherosclerosis in patients with abdominal obesity and coronary artery disease ... Abdominal obesity is associated with specific metabolic abnormalities that ...

| PowerPoint PPT presentation | free to view

HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? PowerPoint PPT Presentation

HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? - HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? GARY A. LOPEZ, M.D. Effects on LDL-C and HDL-C HDL-C Study Week Baseline Wk 6 Wk 12 Wk ...

HDL CHOLESTEROL REVISITED-- A RELIABLE DIAGNOSTIC TOOL OR JUST A PASSING FANCY? GARY A. LOPEZ, M.D. Effects on LDL-C and HDL-C HDL-C Study Week Baseline Wk 6 Wk 12 Wk ...

| PowerPoint PPT presentation | free to view

The REVERSAL Trial PowerPoint PPT Presentation

The REVERSAL Trial - Multicenter, randomized, double-blind, active- controlled trial ... adverse events were constipation, flatulence, dyspepsia and abdominal pain, ...

Multicenter, randomized, double-blind, active- controlled trial ... adverse events were constipation, flatulence, dyspepsia and abdominal pain, ...

| PowerPoint PPT presentation | free to view

Practical Management of Hypertension in Primary Care PowerPoint PPT Presentation

Practical Management of Hypertension in Primary Care - Practical Management of Hypertension in Primary Care Back to Medical School Group Dr Rob Sapsford Consultant Cardiologist Leeds Teaching Hospitals

Practical Management of Hypertension in Primary Care Back to Medical School Group Dr Rob Sapsford Consultant Cardiologist Leeds Teaching Hospitals

| PowerPoint PPT presentation | free to view

Genetic Programming PowerPoint PPT Presentation

Genetic Programming - Fitness function hard to define (how bad is a wrong answer? ... Some outperform previous patents. Balun circuit (4-fold improvement) ...

Fitness function hard to define (how bad is a wrong answer? ... Some outperform previous patents. Balun circuit (4-fold improvement) ...

| PowerPoint PPT presentation | free to view

Ze Yang, Jan Dorman PowerPoint PPT Presentation

Ze Yang, Jan Dorman - Akita???1994???,???????,??14???????????????15??????????????0.81%?4.62%(?14? ???? ... Harukuni Akita, Hitoshi Chiba, Keiko Tsuchihashi, Masahiro Tsuji, Mitsuru ...

Akita???1994???,???????,??14???????????????15??????????????0.81%?4.62%(?14? ???? ... Harukuni Akita, Hitoshi Chiba, Keiko Tsuchihashi, Masahiro Tsuji, Mitsuru ...

| PowerPoint PPT presentation | free to download

Guideline Development Group (GDG) PowerPoint PPT Presentation

Guideline Development Group (GDG) - FH Guidelines in Practice : findings from the DH cascade and audit project and the pilot RCP audit

FH Guidelines in Practice : findings from the DH cascade and audit project and the pilot RCP audit

| PowerPoint PPT presentation | free to view

Rales and other recent trials in heart failure PowerPoint PPT Presentation

Rales and other recent trials in heart failure - ... Val-HeFT y CHARM-Added studies tienen resultados similares. ... The 4D Study. Presented during the Last minute session: Recent results from clinical trials.

... Val-HeFT y CHARM-Added studies tienen resultados similares. ... The 4D Study. Presented during the Last minute session: Recent results from clinical trials.

| PowerPoint PPT presentation | free to download

Dyslipid - Approche 2006 Andr Roussin MD, labo vasc HND Notion de risque CV Di te Pharmacoth rapie Conclusion.org Andr Roussin MD Disclosures AstraZeneca Bristol-Myers ...

Approche 2006 Andr Roussin MD, labo vasc HND Notion de risque CV Di te Pharmacoth rapie Conclusion.org Andr Roussin MD Disclosures AstraZeneca Bristol-Myers ...

| PowerPoint PPT presentation | free to download

P Sever Cochair, B Dahlf Cochair, N Poulter Secretary, H Wedel Statistician, G Beevers, M Caulfield, PowerPoint PPT Presentation

P Sever Cochair, B Dahlf Cochair, N Poulter Secretary, H Wedel Statistician, G Beevers, M Caulfield, - On behalf of the ASCOT Investigators. The Anglo ... Current smoker. Noncurrent smoker. Obese. Nonobese. LVH. No LVH. Older ( 60 years) Younger (60 years) ...

On behalf of the ASCOT Investigators. The Anglo ... Current smoker. Noncurrent smoker. Obese. Nonobese. LVH. No LVH. Older ( 60 years) Younger (60 years) ...

| PowerPoint PPT presentation | free to view

Hyperlipidemia Chapter 23 PowerPoint PPT Presentation

Hyperlipidemia Chapter 23 - Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. ... CHD risk directly correlates with TC & LDL levels in graded, continuous fashion ...

Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. ... CHD risk directly correlates with TC & LDL levels in graded, continuous fashion ...

| PowerPoint PPT presentation | free to view

Everything You Need to Know About Clinical Trials Registration and Results Reporting Requirements PowerPoint PPT Presentation

Everything You Need to Know About Clinical Trials Registration and Results Reporting Requirements - ... month 900,000 Number Percent Trials by Sponsor US Federal (including NIH) 10,777 14% Industry 25,737 32% University, Other 43,091 54% ...

... month 900,000 Number Percent Trials by Sponsor US Federal (including NIH) 10,777 14% Industry 25,737 32% University, Other 43,091 54% ...

| PowerPoint PPT presentation | free to download

STRADIVARIUS Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesi PowerPoint PPT Presentation

STRADIVARIUS Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesi - PAV: primary endpoint. TAV: secondary endpoint -2.2. 0.88. 0.51. 0.25. P 0. ... for rimonabant on the primary endpoint, PAV (P = 0.22), but a favorable effect ...

PAV: primary endpoint. TAV: secondary endpoint -2.2. 0.88. 0.51. 0.25. P 0. ... for rimonabant on the primary endpoint, PAV (P = 0.22), but a favorable effect ...

| PowerPoint PPT presentation | free to view

A Randomized Trial of Rosuvastatin in the Prevention PowerPoint PPT Presentation

A Randomized Trial of Rosuvastatin in the Prevention - ... cardiovascular disease independent of LDL-C levels ... LDL-C 130 mg/dL. CRP ... LDL-C 130 mg/dL 53. hsCRP 2.0 mg/L 37. Withdrew Consent 4. Diabetes 1 ...

... cardiovascular disease independent of LDL-C levels ... LDL-C 130 mg/dL. CRP ... LDL-C 130 mg/dL 53. hsCRP 2.0 mg/L 37. Withdrew Consent 4. Diabetes 1 ...

| PowerPoint PPT presentation | free to view

A Toll-like receptor ok szerepe diabetes mellitusban PowerPoint PPT Presentation

A Toll-like receptor ok szerepe diabetes mellitusban - dr. Reismann P ter Semmelweis Egyetem II.sz. Belgy gy szati Klinika * * RSV bronchiolitis es ly t n veli. IBD s H.pylori okozta gyomor cc.-vel asszoci lt A ...

dr. Reismann P ter Semmelweis Egyetem II.sz. Belgy gy szati Klinika * * RSV bronchiolitis es ly t n veli. IBD s H.pylori okozta gyomor cc.-vel asszoci lt A ...

| PowerPoint PPT presentation | free to download

Risk Factor Modification Rationale for Management of Dyslipidemia PowerPoint PPT Presentation

Risk Factor Modification Rationale for Management of Dyslipidemia - LRC-CPPT Helsinki Heart Study ... Sacks FM et al. N Engl J Med 1996;35:1001 1009. LIPID Study Group. ... Pedersen T. Eur Heart J 1998;19(suppl M):M15 M21. 3.3 ...

LRC-CPPT Helsinki Heart Study ... Sacks FM et al. N Engl J Med 1996;35:1001 1009. LIPID Study Group. ... Pedersen T. Eur Heart J 1998;19(suppl M):M15 M21. 3.3 ...

| PowerPoint PPT presentation | free to view

GUIDELINESWHATS NEW AND WHATS NOT PowerPoint PPT Presentation

GUIDELINESWHATS NEW AND WHATS NOT - GUIDELINES WHATS NEW AND WHATS NOT. WWW.DIABETES.CA/FOR-PROFESSIONALS ... CDA Guidelines. Cardiorenal Prioritization. In All High-risk Patients. ACE inhibitor ...

GUIDELINES WHATS NEW AND WHATS NOT. WWW.DIABETES.CA/FOR-PROFESSIONALS ... CDA Guidelines. Cardiorenal Prioritization. In All High-risk Patients. ACE inhibitor ...

| PowerPoint PPT presentation | free to view

Colesterol y enfermedad coronaria їDуnde estamos? PowerPoint PPT Presentation

Colesterol y enfermedad coronaria їDуnde estamos? - Colesterol y enfermedad coronaria D nde estamos? MT Villarroel Secci n de Cardiolog a. Hospital San Jorge Huesca Reuni n Sociedad Aragonesa de Cardiolog a

Colesterol y enfermedad coronaria D nde estamos? MT Villarroel Secci n de Cardiolog a. Hospital San Jorge Huesca Reuni n Sociedad Aragonesa de Cardiolog a

| PowerPoint PPT presentation | free to download

Peter Reiss - Tolerability and Safety of HIV Treatment Has Improved With Time ... Gilead Sciences. NRTI PI. Altered Fat. Distribution. Dyslipidemia. Insulin Resistance ...

Tolerability and Safety of HIV Treatment Has Improved With Time ... Gilead Sciences. NRTI PI. Altered Fat. Distribution. Dyslipidemia. Insulin Resistance ...

| PowerPoint PPT presentation | free to view

NOVEL BIOMARKERS and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Di PowerPoint PPT Presentation

NOVEL BIOMARKERS and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Di - Unstable plaques have increased leukocytic infiltrates ... Plavix Aspirin. Trade Name. Ticlopidine hydrochloride* Clopidogrel bisulfate ...

Unstable plaques have increased leukocytic infiltrates ... Plavix Aspirin. Trade Name. Ticlopidine hydrochloride* Clopidogrel bisulfate ...

| PowerPoint PPT presentation | free to view

La Protena C Reactiva y JUPITER PowerPoint PPT Presentation

La Protena C Reactiva y JUPITER - El objetivo primario del estudio JUPITER es investigar si el tratamiento ... (incidencia de diabetes mellitus, eventos tromboemb licos venosos, fracturas seas) ...

El objetivo primario del estudio JUPITER es investigar si el tratamiento ... (incidencia de diabetes mellitus, eventos tromboemb licos venosos, fracturas seas) ...

| PowerPoint PPT presentation | free to view

- JUPITER Conclusions Efficacy II Benefits of rosuvastatin were consistent in all sub-groups evaluated regardless of age, sex, ethnicity, ...

JUPITER Conclusions Efficacy II Benefits of rosuvastatin were consistent in all sub-groups evaluated regardless of age, sex, ethnicity, ...

| PowerPoint PPT presentation | free to download

JUPITER - Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women's ... Dr Ridker has served as a consultant to AstraZeneca, Novartis, Merck, Schering ...

Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women's ... Dr Ridker has served as a consultant to AstraZeneca, Novartis, Merck, Schering ...

| PowerPoint PPT presentation | free to view

Kastelein PowerPoint PPT Presentations